Archit Organosys Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 849091,
    "name": "Archit Organosys",
    "stock_name": "Archit Organosys",
    "full_name": "Archit Organosys Ltd",
    "name_url": "stocks-analysis/archit-organosys",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "41.49",
    "chg": 1.64,
    "chgp": "4.12%",
    "dir": 1,
    "prev_price": "39.85",
    "mcapval": "82.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524640,
    "symbol": "",
    "ind_name": "Commodity Chemicals",
    "ind_code": 11,
    "indexname": "",
    "isin": "INE078I01011",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "2.91 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/archit-organosys-849091-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Archit Organosys Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-archit-organosys-ltd-latest-results-good-or-bad-3827583",
        "imagepath": "",
        "date": "2026-02-08 19:13:20",
        "description": "Archit Organosys Ltd has recently reported its financial results for Q3 FY26, showcasing a notable turnaround in net profit, which reached ₹2.43 crores, marking a significant improvement from the previous quarter's loss. This quarter also witnessed a revenue growth of 28.60% for the first half of FY26 compared to the same period last year, indicating strong top-line performance. However, despite these positive developments, the company continues to face significant challenges related to profitability and capital efficiency.\n\nThe operating margin, excluding other income, has seen a decline to 7.69%, down from 10.48% in the previous quarter, highlighting ongoing margin compression. Additionally, the return on equity (ROE) remains critically low at 0.97%, suggesting that the company is struggling to generate adequate returns on its equity capital. This weak capital efficiency raises concerns about the sustaina..."
      },
      {
        "title": "Archit Organosys Q3 FY26: Stellar Turnaround Masks Underlying Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/archit-organosys-q3-fy26-stellar-turnaround-masks-underlying-margin-pressures-3827017",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ArchitOrganosys_quaterlyResult_3827017.png",
        "date": "2026-02-07 20:47:57",
        "description": "Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, has delivered a remarkable turnaround in Q3 FY26, swinging from a loss to profitability with net profit surging to ₹2.43 crores. However, the stock remains under pressure, trading 19.36% below its 52-week high of ₹51.45, as investors grapple with persistent margin erosion and weak return ratios that continue to plague the ₹82-crore market capitalisation company."
      },
      {
        "title": "Are Archit Organosys Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-archit-organosys-ltd-latest-results-good-or-bad-3826853",
        "imagepath": "",
        "date": "2026-02-07 19:19:25",
        "description": "Archit Organosys Ltd's latest financial results for Q2 FY26 reflect significant operational challenges. The company reported net sales of ₹26.39 crores, which indicates a sequential decline of 5.99% from the previous quarter and a year-on-year contraction of 7.27%. This decline in revenue is accompanied by a sharp drop in net profit, which fell to ₹0.37 crores, representing a substantial decrease of 76.43% quarter-on-quarter and an 87.91% decline compared to the same quarter last year.\n\nThe operating margin has also come under pressure, recorded at 8.00%, down from higher levels in previous periods, highlighting ongoing issues with profitability. The return on equity (ROE) averaged 8.85%, but the latest figure shows a concerning drop to just 0.97%, indicating that the company is struggling to generate adequate returns on shareholder capital.\n\nFurthermore, the company's reliance on other income has become mo..."
      },
      {
        "title": "When is the next results date for Archit Organosys Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-archit-organosys-ltd-3821211",
        "imagepath": "",
        "date": "2026-02-04 23:16:57",
        "description": "The next results date for Archit Organosys Ltd is scheduled for 07 February 2026...."
      },
      {
        "title": "Archit Organosys Downgraded to Strong Sell Amid Bearish Technicals and Weak Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-downgraded-to-strong-sell-amid-bearish-technicals-and-weak-fundamentals-3819907",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ArchitOrganosys_mojoScore_3819907.png",
        "date": "2026-02-04 08:14:17",
        "description": "Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 3 February 2026. This revision reflects deteriorating technical indicators, subdued financial trends, and concerns over valuation and quality metrics, signalling caution for investors amid ongoing market challenges."
      },
      {
        "title": "Archit Organosys Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-upgraded-to-sell-a-detailed-analysis-of-the-rating-change-3808850",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ArchitOrganosys_mojoScore_3808850.png",
        "date": "2026-01-29 08:07:05",
        "description": "Archit Organosys Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid mixed fundamental performance. While the company’s financial trends show positive quarterly results and improved profitability, concerns remain over its long-term growth and valuation metrics. This nuanced upgrade reflects a cautious optimism among analysts, balancing recent momentum against structural challenges in the commodity chemicals sector."
      },
      {
        "title": "Archit Organosys Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3799589",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ArchitOrganosys_mojoScore_3799589.png",
        "date": "2026-01-22 08:06:31",
        "description": "Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 21 January 2026. This revision reflects a deterioration in technical indicators, persistent fundamental weaknesses, and valuation concerns despite recent positive quarterly financial results. The company’s Mojo Score now stands at 26.0, underscoring the cautious stance adopted by analysts."
      },
      {
        "title": "Archit Organosys Ltd Upgraded to Sell on Technical Improvements Despite Mixed Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-upgraded-to-sell-on-technical-improvements-despite-mixed-fundamentals-3793829",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ArchitOrganosys_mojoScore_3793829.png",
        "date": "2026-01-19 08:05:42",
        "description": "Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating upgraded from Strong Sell to Sell as of 16 January 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental headwinds. While the company’s financial performance shows signs of improvement, long-term growth and quality metrics remain subdued, prompting a cautious stance from analysts."
      },
      {
        "title": "Archit Organosys Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/archit-organosys-ltd-downgraded-to-strong-sell-amid-technical-and-fundamental-concerns-3789383",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ArchitOrganosys_mojoScore_3789383.png",
        "date": "2026-01-12 08:06:10",
        "description": "Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 9 January 2026. This revision reflects a deterioration in technical indicators, persistent fundamental weaknesses, and valuation concerns despite recent positive quarterly financial results. The downgrade signals heightened caution for investors amid mixed signals across quality, valuation, financial trends, and technical analysis."
      }
    ],
    "total": 118,
    "sid": "849091",
    "stock_news_url": "https://www.marketsmojo.com/news/archit-organosys-849091"
  },
  "announcements": [
    {
      "caption": "Approval Of Unaudited Financial Result For The Quarter And Nine Months Ended 31.12.2025",
      "datetime": "07-Feb-2026",
      "details": "Approval of unaudited financial result for the quarter and nine months ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Approval Of Unaudited Financial Result Of The Company For The Quarter And Nine Month Ended December 31 2025",
      "datetime": "07-Feb-2026",
      "details": "Approval of unaudited Financial result of the Company for the quarter and nine month ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Prior Intimation Of Board Meeting To Consider And Approve The Unaudited Financial Result For The Quarter Ended 31.12.2025",
      "datetime": "03-Feb-2026",
      "details": "Archit Organosys Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve Unaudited Financial Result for the quarter ended 31.12.2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Archit Organosys Ltd has declared <strong>5%</strong> dividend, ex-date: 22 Sep 25",
          "dt": "2025-09-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Archit Organosys Ltd has announced <strong>2:1</strong> rights issue, ex-date: 09 Feb 17",
          "dt": "2017-02-09",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Are Archit Organosys Ltd latest results good or bad?

2026-02-08 19:13:20

Archit Organosys Ltd has recently reported its financial results for Q3 FY26, showcasing a notable turnaround in net profit, which reached ₹2.43 crores, marking a significant improvement from the previous quarter's loss. This quarter also witnessed a revenue growth of 28.60% for the first half of FY26 compared to the same period last year, indicating strong top-line performance. However, despite these positive developments, the company continues to face significant challenges related to profitability and capital efficiency. The operating margin, excluding other income, has seen a decline to 7.69%, down from 10.48% in the previous quarter, highlighting ongoing margin compression. Additionally, the return on equity (ROE) remains critically low at 0.97%, suggesting that the company is struggling to generate adequate returns on its equity capital. This weak capital efficiency raises concerns about the sustaina...

Read full news article

Archit Organosys Q3 FY26: Stellar Turnaround Masks Underlying Margin Pressures

2026-02-07 20:47:57

Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, has delivered a remarkable turnaround in Q3 FY26, swinging from a loss to profitability with net profit surging to ₹2.43 crores. However, the stock remains under pressure, trading 19.36% below its 52-week high of ₹51.45, as investors grapple with persistent margin erosion and weak return ratios that continue to plague the ₹82-crore market capitalisation company.

Read full news article

Are Archit Organosys Ltd latest results good or bad?

2026-02-07 19:19:25

Archit Organosys Ltd's latest financial results for Q2 FY26 reflect significant operational challenges. The company reported net sales of ₹26.39 crores, which indicates a sequential decline of 5.99% from the previous quarter and a year-on-year contraction of 7.27%. This decline in revenue is accompanied by a sharp drop in net profit, which fell to ₹0.37 crores, representing a substantial decrease of 76.43% quarter-on-quarter and an 87.91% decline compared to the same quarter last year. The operating margin has also come under pressure, recorded at 8.00%, down from higher levels in previous periods, highlighting ongoing issues with profitability. The return on equity (ROE) averaged 8.85%, but the latest figure shows a concerning drop to just 0.97%, indicating that the company is struggling to generate adequate returns on shareholder capital. Furthermore, the company's reliance on other income has become mo...

Read full news article

When is the next results date for Archit Organosys Ltd?

2026-02-04 23:16:57

The next results date for Archit Organosys Ltd is scheduled for 07 February 2026....

Read full news article

Archit Organosys Downgraded to Strong Sell Amid Bearish Technicals and Weak Fundamentals

2026-02-04 08:14:17

Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 3 February 2026. This revision reflects deteriorating technical indicators, subdued financial trends, and concerns over valuation and quality metrics, signalling caution for investors amid ongoing market challenges.

Read full news article

Archit Organosys Ltd Upgraded to Sell: A Detailed Analysis of the Rating Change

2026-01-29 08:07:05

Archit Organosys Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid mixed fundamental performance. While the company’s financial trends show positive quarterly results and improved profitability, concerns remain over its long-term growth and valuation metrics. This nuanced upgrade reflects a cautious optimism among analysts, balancing recent momentum against structural challenges in the commodity chemicals sector.

Read full news article

Archit Organosys Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals

2026-01-22 08:06:31

Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 21 January 2026. This revision reflects a deterioration in technical indicators, persistent fundamental weaknesses, and valuation concerns despite recent positive quarterly financial results. The company’s Mojo Score now stands at 26.0, underscoring the cautious stance adopted by analysts.

Read full news article

Archit Organosys Ltd Upgraded to Sell on Technical Improvements Despite Mixed Fundamentals

2026-01-19 08:05:42

Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating upgraded from Strong Sell to Sell as of 16 January 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental headwinds. While the company’s financial performance shows signs of improvement, long-term growth and quality metrics remain subdued, prompting a cautious stance from analysts.

Read full news article

Archit Organosys Ltd Downgraded to Strong Sell Amid Technical and Fundamental Concerns

2026-01-12 08:06:10

Archit Organosys Ltd, a player in the commodity chemicals sector, has seen its investment rating downgraded from Sell to Strong Sell as of 9 January 2026. This revision reflects a deterioration in technical indicators, persistent fundamental weaknesses, and valuation concerns despite recent positive quarterly financial results. The downgrade signals heightened caution for investors amid mixed signals across quality, valuation, financial trends, and technical analysis.

Read full news article

View All News